首页> 美国卫生研究院文献>other >Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase
【2h】

Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase

机译:将胸苷激酶活性扩展至人类脱氧胞苷激酶的催化库

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Salvage of nucleosides in the cytosol of human cells is carried out by deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1). Whereas TK1 is only responsible for thymidine phosphorylation, dCK is capable of converting dC, dA, and dG into their monophosphate forms. Using structural data on dCK we predicted that select mutations at the active site would, in addition to making the enzyme faster, expand the catalytic repertoire of dCK to include thymidine. Specifically, we hypothesized that steric repulsion between the methyl group of the thymine base and Arg104 is the main factor preventing the phosphorylation of thymidine by wild type dCK. Here we present kinetic data on several dCK variants where Arg104 has been replaced by select residues, all performed in combination with the mutation of Asp133 to an alanine. We show that several hydrophobic residues at position 104 endow dCK with thymidine kinase activity. Depending on the exact nature of the mutations, the enzyme’s substrate preference is modified. The R104M-D133A double mutant is a pyrimidine-specific enzyme due to large Km values with purines. Crystal structure of the double mutant R104M-D133A in complex with the L-form of thymidine supplies a structural explanation for the ability of this variant to phosphorylate thymidine and thymidine analogs. The replacement of Arg104 by a smaller residue allows L-dT to bind deeper into the active site, making space for the C5-methyl group of the thymine base. The unique catalytic properties of several of the mutants make them good candidates for suicide gene/protein therapy applications.
机译:通过脱氧胞苷激酶(dCK)和胸苷激酶1(TK1)进行人类细胞质中核苷的挽救。 TK1仅负责胸苷的磷酸化,而dCK能够将dC,dA和dG转化为单磷酸形式。使用dCK上的结构数据,我们预测在活性位点的选择突变除了使酶更快之外,还将扩大dCK的催化范围,使其包括胸苷。具体而言,我们假设胸腺嘧啶碱基的甲基与Arg104之间的空间排斥是阻止野生型dCK引起胸苷磷酸化的主要因素。在这里,我们介绍了几种dCK变体的动力学数据,其中Arg104已被选择的残基取代,所有残基均与Asp133突变为丙氨酸结合进行。我们显示,在104位的几个疏水残基赋予dCK胸苷激酶活性。根据突变的确切性质,可以修改酶的底物偏好。 R104M-D133A双突变体是嘧啶特异的酶,因为嘌呤的Km值较大。双突变体R104M-D133A与胸苷的L型复合的晶体结构为该变体磷酸化胸苷和胸苷类似物的能力提供了结构解释。用较小的残基取代Arg104可使L-dT更深地结合到活性位点,从而为胸腺嘧啶碱基的C5-甲基留出空间。几个突变体的独特催化特性使其成为自杀基因/蛋白质治疗应用的良好候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号